Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Esperion Theraptc (ESPR)

Esperion Theraptc (ESPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 431,507
  • Shares Outstanding, K 197,035
  • Annual Sales, $ 116,330 K
  • Annual Income, $ -209,250 K
  • EBIT $ 16 M
  • EBITDA $ 18 M
  • 60-Month Beta 1.01
  • Price/Sales 3.71
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 181.40% ( +50.05%)
  • Historical Volatility 129.88%
  • IV Percentile 98%
  • IV Rank 39.83%
  • IV High 393.52% on 09/20/24
  • IV Low 40.97% on 06/13/24
  • Put/Call Vol Ratio 0.50
  • Today's Volume 704
  • Volume Avg (30-Day) 4,098
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 95,846
  • Open Int (30-Day) 107,325

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.12
  • Number of Estimates 5
  • High Estimate -0.09
  • Low Estimate -0.16
  • Prior Year -0.50
  • Growth Rate Est. (year over year) +76.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.84 +20.65%
on 12/13/24
3.94 -43.65%
on 12/09/24
-0.30 (-11.90%)
since 11/22/24
3-Month
1.58 +40.51%
on 10/02/24
3.94 -43.65%
on 12/09/24
+0.59 (+36.20%)
since 09/23/24
52-Week
1.58 +40.51%
on 10/02/24
3.94 -43.65%
on 12/09/24
-0.14 (-5.93%)
since 12/22/23

Most Recent Stories

More News
Esperion Secures $150 Million Loan and $100 Million Convertible Note to Restructure Existing Convertible Debt

Esperion secures $150M term loan and $100M convertible note to repay $210M of existing convertible debt.Quiver AI SummaryEsperion has announced the completion of financing transactions aimed at reducing...

ESPR : 2.24 (+2.28%)
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

ESPR : 2.24 (+2.28%)
Esperion Announces $210 Million Convertible Debt Financing

ESPR : 2.24 (+2.28%)
Esperion Announces Licensing Agreement with Neopharm Israel for NEXLETOL® and NEXLIZET® Commercialization

Esperion licenses NEXLETOL and NEXLIZET to Neopharm Israel, receiving upfront payments and royalties from sales in the region.Quiver AI SummaryEsperion Therapeutics has announced a licensing agreement...

ESPR : 2.24 (+2.28%)
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

ESPR : 2.24 (+2.28%)
ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada

Esperion Therapeutics, Inc. ESPR announced that it has filed new drug submissions (NDSs) in Canada to seek approval for its once-daily, oral non-statin drugs Nexletol (bempedoic acid) and Nexlizet as a...

ESPR : 2.24 (+2.28%)
IMCR : 28.18 (-0.53%)
CSTL : 27.33 (-0.73%)
SPRO : 0.9654 (+1.08%)
Esperion Submits New Drug Applications for NEXLETOL and NEXLIZET to Health Canada to Address LDL Cholesterol and Cardiovascular Risk

Esperion submits NDSs for NEXLETOL and NEXLIZET to Health Canada, targeting LDL-C reduction and cardiovascular risk.Quiver AI SummaryEsperion has filed New Drug Submissions for its oral non-statin medications,...

ESPR : 2.24 (+2.28%)
Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk

ESPR : 2.24 (+2.28%)
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia

ESPR : 2.24 (+2.28%)
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference

ESPR : 2.24 (+2.28%)

Business Summary

Esperion Therapeutics, Inc. is a pharmaceutical company focused on the development of oral lipid-management treatments for cardiovascular diseases caused by elevated levels of LDL-C (bad cholesterol).

See More

Key Turning Points

3rd Resistance Point 2.35
2nd Resistance Point 2.29
1st Resistance Point 2.24
Last Price 2.24
1st Support Level 2.13
2nd Support Level 2.07
3rd Support Level 2.02

See More

52-Week High 3.94
Fibonacci 61.8% 3.04
Fibonacci 50% 2.76
Fibonacci 38.2% 2.48
Last Price 2.24
52-Week Low 1.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar